Zhongyianke Biotech, a Tianjin vaccine maker, raised $36 million in a Series A financing led by Shenzhen Qianhai Beizeng Asset Management. Founded in 2001, Zhongyianke has launched a flu vaccine and is conducting clinical trials on four other human vaccines: a tetravalent influenza vaccine, a tetravalent meningococcal vaccine, a rabies vaccine, and a rubella vaccine. The company holds 14 China patents. In addition to its operations in Tianjin, the company has an R&D center in Beijing and a production facility in Liaoning Province. Source: China Biotoday
